These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 19434735)

  • 21. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.
    Riis A; Martinsen TC; Waldum HL; Fossmark R
    Scand J Gastroenterol; 2012 Jun; 47(6):649-57. PubMed ID: 22472026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
    Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
    J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.
    Tozer P; Ng SC; Siddiqui MR; Plamondon S; Burling D; Gupta A; Swatton A; Tripoli S; Vaizey CJ; Kamm MA; Phillips R; Hart A
    Inflamm Bowel Dis; 2012 Oct; 18(10):1825-34. PubMed ID: 22223472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
    Martín-de-Carpi J; Pociello N; Varea V
    J Crohns Colitis; 2010 Nov; 4(5):594-8. PubMed ID: 21122566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
    Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
    Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.
    Watanabe M; Hibi T; Mostafa NM; Chao J; Arora V; Camez A; Petersson J; Thakkar R
    J Crohns Colitis; 2014 Nov; 8(11):1407-16. PubMed ID: 24874893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized controlled trials in maintenance of remission in Crohn's disease.
    D'Incà R; Caccaro R
    Rev Recent Clin Trials; 2012 Nov; 7(4):270-83. PubMed ID: 23092231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease.
    Choi GK; Collins SD; Greer DP; Warren L; Dowson G; Clark T; Hamlin PJ; Ford AC
    J Crohns Colitis; 2014 May; 8(5):375-83. PubMed ID: 24129316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease.
    Horneff G; Seyger MMB; Arikan D; Kalabic J; Anderson JK; Lazar A; Williams DA; Wang C; Tarzynski-Potempa R; Hyams JS
    J Pediatr; 2018 Oct; 201():166-175.e3. PubMed ID: 30054164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-term response to adalimumab in childhood inflammatory bowel disease.
    Noe JD; Pfefferkorn M
    Inflamm Bowel Dis; 2008 Dec; 14(12):1683-7. PubMed ID: 18618629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
    Hanauer SB; Sandborn WJ; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh D; Panaccione R; Wolf D; Pollack P
    Gastroenterology; 2006 Feb; 130(2):323-33; quiz 591. PubMed ID: 16472588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Adalimumab therapy in Crohn's disdease].
    Baryshnikov EN; Lazebnik LB; Parfenov AI
    Eksp Klin Gastroenterol; 2009; (5):92-8. PubMed ID: 20205331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children.
    Hyams JS; Griffiths A; Markowitz J; Baldassano RN; Faubion WA; Colletti RB; Dubinsky M; Kierkus J; Rosh J; Wang Y; Huang B; Bittle B; Marshall M; Lazar A
    Gastroenterology; 2012 Aug; 143(2):365-74.e2. PubMed ID: 22562021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.
    Burmester GR; Panaccione R; Gordon KB; McIlraith MJ; Lacerda AP
    Ann Rheum Dis; 2013 Apr; 72(4):517-24. PubMed ID: 22562972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
    Rutgeerts P; Van Assche G; Sandborn WJ; Wolf DC; Geboes K; Colombel JF; Reinisch W; ; Kumar A; Lazar A; Camez A; Lomax KG; Pollack PF; D'Haens G
    Gastroenterology; 2012 May; 142(5):1102-1111.e2. PubMed ID: 22326435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies.
    Hanauer SB
    Rev Gastroenterol Disord; 2004; 4 Suppl 3():S18-24. PubMed ID: 15580149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.